Search Results - "Khoo, Stella"

The role of the tumor suppressor p53 pathway in the cellular DNA damage response to zinc oxide nanoparticles by Ng, Kee Woei, Khoo, Stella P.K, Heng, Boon Chin, Setyawati, Magdiel I, Tan, Eng Chok, Zhao, Xinxin, Xiong, Sijing, Fang, Wanru, Leong, David T, Loo, Joachim S.C

“…Abstract In this paper, we explored how ZnO nanoparticles cross-interact with a critical tumor suppressive pathway centered around p53, which is one of the…”
Get full text

Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma by Othman, Tamer, Frankel, Paul, Allen, Pamela, Popplewell, Leslie L, Shouse, Geoffrey, Siddiqi, Tanya, Danilov, Alexey V, Ruel, Nora, Daniels, Shari, Peters, Lacolle, Khoo, Stella, Rosen, Steven T, Sharon, Elad, Villalona-Calero, Miguel, Ruel, Christopher, Tuscano, Joseph, Herrera, Alex F

“…Patients with relapsed/refractory (R/R) transformed diffuse large B-cell lymphoma (DLBCL) from indolent B-cell lymphomas, including Richter transformation…”
Get full text

Fluorescence techniques used to measure interactions between hydroxyapatite nanoparticles and epidermal growth factor receptors by Kathawala, Mustafa H., Khoo, Stella P. K., Sudhaharan, Thankiah, Zhao, Xinxin, Say Chye Loo, Joachim, Ahmed, Sohail, Woei Ng, Kee

“…The potential applications of nanomaterials in therapeutics are immense and to fully explore this potential, it is important to understand the interaction of…”
Get full text

Cytotoxic and genotoxic characterization of titanium dioxide, gadolinium oxide, and poly(lactic-co-glycolic acid) nanoparticles in human fibroblasts by Setyawati, Magdiel Inggrid, Khoo, Pheng Kian Stella, Eng, Bao Hui, Xiong, Sijing, Zhao, Xinxin, Das, Gautom Kumar, Tan, Timothy Thatt-Yang, Loo, Joachim Say Chye, Leong, David Tai, Ng, Kee Woei

“…Engineered nanomaterials have become prevalent in our everyday life. While the popularity of using nanomaterials in consumer products continues to rise,…”
Get full text

Atezolizumab Combined with Immunogenic Salvage Chemoimmunotherapy (R-GemOx+Atezo) in Patients with Transformed Diffuse Large B-Cell Lymphoma by Herrera, Alex F., Othman, Tamer, Frankel, Paul, Allen, Pamela, Popplewell, Leslie L., Shouse, Geoffrey, Siddiqi, Tanya, Danilov, Alexey V., Ruel, Nora, Daniels, Shari, Peters, Lacolle, Khoo, Stella, Rosen, Steven T., Sharon, Elad, Tuscano, Joseph M

“…Introduction: Diffuse large B-cell lymphomas (DLBCL) transformed from indolent B-cell non-Hodgkin lymphomas (B-NHL) or Richter transformation (RT) from chronic…”
Get full text

Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium – an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879 by Quinn, David I., Tsao-Wei, Denice D., Twardowski, Przemyslaw, Aparicio, Ana M., Frankel, Paul, Chatta, Gurkamal, Wright, John J., Groshen, Susan G., Khoo, Stella, Lenz, Heinz-Josef, Lara, Primo N., Gandara, David R., Newman, Edward

“…Summary Background: Until the advent of T cell check point inhibitors standard second-line therapy for patients with metastatic urothelial cancer (mUC) was…”
Get full text

A mismatch between methods and objectives in phase I drug development: Statistical limitations and personalized medicine—A California Cancer Consortium (CCC) study by Frankel, Paul Henry, Shibata, Stephen, Groshen, Susan G., Longmate, Jeff, Pal, Sumanta Kumar, Khoo, Stella, Newman, Edward M.

“…Abstract only 2538 Background: Patient variation in drug response and toxicity impacts all phases of drug development. While detailed sample-size calculations…”
Get full text